Compile Data Set for Download or QSAR
Report error Found 48 Enz. Inhib. hit(s) with all data for entry = 3011
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388296(US10294230, Compound E1-2.2)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388296(US10294230, Compound E1-2.2)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388296(US10294230, Compound E1-2.2)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 14.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 14.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 14.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388299(US10294230, Compound E1-1.3 | US10584127, Compound...)
Affinity DataIC50: 14.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388299(US10294230, Compound E1-1.3 | US10584127, Compound...)
Affinity DataIC50: 14.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388299(US10294230, Compound E1-1.3 | US10584127, Compound...)
Affinity DataIC50: 14.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388298(US10294230, Compound E1-8.2)
Affinity DataIC50: 17nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388298(US10294230, Compound E1-8.2)
Affinity DataIC50: 17nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388298(US10294230, Compound E1-8.2)
Affinity DataIC50: 17nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388294(US10294230, Compound E1-1.2 | US10584127, Compound...)
Affinity DataIC50: 21nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388294(US10294230, Compound E1-1.2 | US10584127, Compound...)
Affinity DataIC50: 21nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388294(US10294230, Compound E1-1.2 | US10584127, Compound...)
Affinity DataIC50: 21nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388303(US10294230, Compound E1-21.26 | US10584127, Compou...)
Affinity DataIC50: 38.7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388303(US10294230, Compound E1-21.26 | US10584127, Compou...)
Affinity DataIC50: 38.7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388303(US10294230, Compound E1-21.26 | US10584127, Compou...)
Affinity DataIC50: 38.7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 42.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 42.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 42.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388297(US10294230, Compound E1-9.2)
Affinity DataIC50: 48.2nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388297(US10294230, Compound E1-9.2)
Affinity DataIC50: 48.2nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388297(US10294230, Compound E1-9.2)
Affinity DataIC50: 48.2nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388295(US10294230, Compound E2-1.2 | US10584127, Compound...)
Affinity DataIC50: 156nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388295(US10294230, Compound E2-1.2 | US10584127, Compound...)
Affinity DataIC50: 156nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388295(US10294230, Compound E2-1.2 | US10584127, Compound...)
Affinity DataIC50: 156nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 4.50E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388298(US10294230, Compound E1-8.2)
Affinity DataIC50: 5.90E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388298(US10294230, Compound E1-8.2)
Affinity DataIC50: 6.80E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 1.00E+4nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388294(US10294230, Compound E1-1.2 | US10584127, Compound...)
Affinity DataIC50: 4.00E+4nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388294(US10294230, Compound E1-1.2 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388295(US10294230, Compound E2-1.2 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388296(US10294230, Compound E1-2.2)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388297(US10294230, Compound E1-9.2)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388298(US10294230, Compound E1-8.2)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388299(US10294230, Compound E1-1.3 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388303(US10294230, Compound E1-21.26 | US10584127, Compou...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent